by Sheela Philomena on  October 23, 2016 at 3:43 PM Research News
New mechanism explaining the inadequate immune defense against chronic viral infection has been discovered by University of Basel scientists. These results may open up new avenues for vaccine development. They have been published in the journal Science Immunology.

In the course of an infection or upon vaccination, specialized cells of our immune system, so-called B cells, produce antibodies that bind viruses and inactivate them. In the context of chronic viral infections such as HIV or hepatitis C virus, however, antibody production by B cells is quantitatively inadequate and starts too late.
World Polio Day 2016
Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection: Study

A team of scientists headed by Prof. Daniel Pinschewer at the Department of Biomedicine, University of Basel, reports that the inadequate antibody response to chronic viral diseases is due to the strong inflammatory reaction upon infection. While most pronounced at the onset of an infection, inflammation can persist for decades, especially in HIV/AIDS.


Hasty immune response lasts only short-term

Under the influence of inflammatory messengers, so called interferons, B cells produce as many antibodies as they possibly can. Unfortunately, this hasty response occurs at the expense of sustainability. B cells that turn on antibody production too quickly lose their potential to proliferate and die shortly thereafter. As a consequence, the immune response takes an impetuous start but subsides rapidly.

The scientists assume that this panic reaction of B cells reflects a mechanism ensuring an optimized response to acute life threatening infections. In the context of chronic infections, however, the battle is not decided within a matter of days, but rather only after months or years. Under these circumstances, the hasty reaction of our body seems inappropriate and may actually favor the virus.

Cornerstone for new vaccines


For viral diseases such as HIV or hepatitis C protective vaccines remain unavailable.

Source: Eurekalert

Most Popular on Medindia